Feb 042019

Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer. Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.Content: Chapter 1 Introduction (pages 1–5): George C. PrendergastChapter 2 Molecular Cancer Therapeutics: Will the Promise be Fulfilled? (pages 7–40): Beverly A. TeicherChapter 3 Cancer Genetics and Drug Target Selection (pages 41–53): Guo?Jun Zhang and William G. KaelinChapter 4 RNA Interference in Mammals: Journey to the Center of Human Disease (pages 55–72): Patrick J. Paddison and Gregory J. HannonChapter 5 Applications and Issues for Tissue Arrays in Target and Drug Discovery (pages 73–90): Eric Jonasch, Kim?Anh Do, Christopher Logothetis and Timothy J. McDonnellChapter 6 Protein Transduction Strategies for Target and Mechanism Validation (pages 91–118): Sergei A. Ezhevsky and Steven F. DowdyChapter 7 Drug Screening: Assay Development Issues (pages 119–140): Steven S. Carroll, James Inglese, Shi?Shan Mao and David B. OlsenChapter 8 Gene Microarray Technologies for Cancer Drug Discovery and Development (pages 141–186): Robert H. te Poele, Paul A. Clarke and Paul WorkmanChapter 9 Transgenic Mouse Models of Cancer (pages 187–202): T. J. Bowen and A. Wynshaw?BorisChapter 10 Transgenic Versus Xenograft Mouse Models of Cancer: Utility and Issues (pages 203–226): Ming Liu, W. Robert Bishop, Yaolin Wang and Paul KirschmeierChapter 11 Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring (pages 227–254): Robert B. Lobell, Nancy E. Kohl and Laura Sepp?LorenzinoChapter 12 Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and Development (pages 255–286): Pamela A. Benfield and Bruce D. CarChapter 13 Clinical Development Issues (pages 287–306): Steven D. Averbuch, Michael K. Wolf, Basil F. El?Rayes and Patricia M. LoRussoChapter 14 Intellectual Property and Commercialization Issues in Drug Discovery (pages 307–327): Lisa Gail Malseed
Share Button

Sorry, the comment form is closed at this time.